Related Experiment Video
Updated: Jun 22, 2025
Sample Preparation for Mass Spectrometry-based Identification of RNA-binding Regions
Published on: September 28, 2017
A Proteomics Approach Identifies RREB1 as a Crucial Molecular Target of Imidazo-Pyrazole Treatment in SKMEL-28
Erika Iervasi1, Gabriela Coronel Vargas1, Tiziana Bachetti1
1IRCCS Ospedale Policlinico San Martino, Proteomics and Mass Spectrometry Unit, L.go. R. Benzi, 10, 16132 Genova, Italy.
Abstract:
Cutaneous melanoma is the most dangerous and deadly form of human skin malignancy. Despite its rarity, it accounts for a staggering 80% of deaths attributed to cutaneous cancers overall. Moreover, its final stages often exhibit resistance to drug treatments, resulting in unfavorable outcomes. Hence, ensuring access to novel and improved chemotherapeutic agents is imperative for patients grappling with this severe ailment. Pyrazole and its fused systems derived thereof are heteroaromatic moieties widely employed in medicinal chemistry to develop effective drugs for various therapeutic areas, including inflammation, pain, oxidation, pathogens, depression, and fever. In a previous study, we described the biochemical properties of a newly synthesized group of imidazo-pyrazole compounds. In this paper, to improve our knowledge of the pharmacological properties of these molecules, we conduct a differential proteomic analysis on a human melanoma cell line treated with one of these imidazo-pyrazole derivatives. Our results detail the changes to the SKMEL-28 cell line proteome induced by 24, 48, and 72 h of 3e imidazo-pyrazole treatment. Notably, we highlight the down-regulation of the Ras-responsive element binding protein 1 (RREB1), a member of the zinc finger transcription factors family involved in the tumorigenesis of melanoma. RREB1 is a downstream element of the MAPK pathway, and its activation is mediated by ERK1/2 through phosphorylation.
Insights
This study investigated the effects of an imidazo-pyrazole derivative on melanoma cells, revealing a key protein
Area of Science:
- Medicinal Chemistry
- Proteomics
- Oncology
Background:
- Cutaneous melanoma is a deadly skin cancer with treatment resistance.
- Pyrazole derivatives are promising in drug development.
- Imidazo-pyrazole compounds show potential therapeutic applications.
Purpose of the Study:
- To investigate the pharmacological properties of a novel imidazo-pyrazole derivative.
- To understand the molecular mechanisms of this compound in melanoma.
- To identify potential therapeutic targets in melanoma treatment.
Main Methods:
- Differential proteomic analysis of human melanoma cell line (SKMEL-28).
- Treatment of cells with an imidazo-pyrazole derivative (compound 3e) for 24, 48, and 72 hours.
- Analysis of proteome changes induced by the compound.
Main Results:
- Identified significant proteome alterations in SKMEL-28 cells.
- Highlighted the down-regulation of Ras-responsive element binding protein 1 (RREB1).
- RREB1, a transcription factor involved in melanoma tumorigenesis, is a downstream element of the MAPK pathway.
Conclusions:
- The imidazo-pyrazole derivative impacts melanoma cell proteome.
- Down-regulation of RREB1 suggests a potential therapeutic mechanism.
- Further research into RREB1 and its pathway could lead to new melanoma treatments.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:38Mitogens and the Cell Cycle